MiNA Therapeutics secures £23m Series A funding led by aMoon to advance RNA therapeutics
The financing round was led by aMoon and will support clinical trials and research pipelines.
MiNA Therapeutics is a biotechnology company pioneering small activating RNA therapeutics to restore or boost normal cell functions. The firm focuses initially on developing treatments for cancer and genetic diseases.
MiNA Therapeutics has secured £23m in Series A equity financing led by aMoon, with backing from existing investors. The fresh capital will be directed towards advancing the clinical development of the company lead candidate, MTL-CEBPA, in combination treatments for cancer, alongside expanding its research pipeline into additional disease areas. MTS Securities acted as the exclusive placement agent for the transaction.
From the founder
"Since the inception of MiNA Therapeutics, we have been focused on advancing the Company by validating our innovative therapeutic approach in patients and establishing strategic collaborations with leading academic institutions and industry partners,"
Robert Habib
CEO at MiNA Therapeutics
Investor perspective
"To date, MiNA’s innovative small activating RNA therapeutic approach has demonstrated the potential to modulate previously undruggable targets in difficult-to-treat indications such as liver cancer,"
Gur Roshwalb
Managing Director, aMoon
Use of funds
- 01Fund research and development
- 02Continue product development
Investors
Categories
About the company
MiNA Therapeutics
MiNA Therapeutics develops small activating RNA medicines to restore normal cell function.